Barclays Maintains Equal-Weight on Amrize, Lowers Price Target to $40
Benzinga Newsdesk 1 week ago
Analyst RatingsNewsPrice Target
Barclays analyst Adam Seiden maintains Amrize (NYSE:AMRZ) with a Equal-Weight and lowers the price target from $55 to $40.
Barclays analyst Adam Seiden maintains Amrize (NYSE:AMRZ) with a Equal-Weight and lowers the price target from $55 to $40.